Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — IPO Roadshow (October 2019)
16 slides from Scopus Biopharma's IPO roadshow presentation, Oct 2, 2019
Slide 1: Building the Future of Cannabinoid Therapeutics
Building the Future of Cannabinoid Therapeutics Corporate Presentation October 2019 Issuer Free Writing Prospectus Dated October 2, 2019 Filed pursuant to Rule 433 under the Securities Act of 1933, as amended, in connection with Registration Statement No. 333 - 23218 9
Slide 2: Disclaimers
Disclaimers General Scopus BioPharma Inc . (the “Company”) has filed with the U . S . Securities and Exchange Commission (the “SEC”) a registration statement containing a preliminary prospectus relating to the offering of its securities to which this communication relates . Before you invest, you sh
Slide 3: Corporate Overview
Corporate Overview 2 Building a global biopharmaceutical company focused on developing novel cannabinoid therapeutics ● New chemical entities (“NCEs”) and proprietary compounds and molecules Focusing on diseases with unmet and compelling medical needs Using established clinical protocols and guideli
Slide 4: Corporate Overview (Cont.)
Corporate Overview (Cont.) 3 Strategic alliances and licenses with leading world - renowned academic and research institutions Robust and growing patent portfolio with three issued patents and numerous pending patents Highly accomplished leadership team fully aligned with investors through significa
Slide 5: Targeting Conditions With Unmet and Compelling Medical Needs
Targeting Conditions With Unmet and Compelling Medical Needs 4 (1) As per the NIH (2) Appropriate annual procedures as per GBI Research (3) Assumes annual treatment cost of $50,000 per year (4) Assumes cost of $300 per procedure Systemic Sclerosis Opioid - sparing, Pain - specific Anesthetics Patien
Slide 6: Product Development Pipeline
Product Development Pipeline 5 Drug Candidate Indication(s) Lead Selection Pre - Clinical Testing IND - Enabling Studies Phase I Phase II Phase III MRI - 1867 Systemic Sclerosis (Orphan Drug Indication) SBP - 101 Opioid - sparing, Pain - selective Anesthetic ( 505(b )(2) Regulatory Pathway) Novel Du
Slide 7: Strategic Relationships
Strategic Relationships U.S.’s preeminent medical research institution NIH spent over $140 million in 2017 on cannabinoid research ● Over 330 research projects ● $36 million across 70 research projects on the therapeutic properties of cannabinoids We licensed dual - action cannabinoid receptor media
Slide 8: Systemic Sclerosis (MRI-1867)
Systemic Sclerosis (MRI - 1867) MRI - 1867 is a proprietary, dual - action, peripherally - restricted NCE CB 1 receptor inverse agonist and inhibitor of iNOS ● Over activation of CB 1 and iNOS has been implicated in the pathophysiology of systemic sclerosis, including fibrosis of the skin, lung, kid
Slide 9: MRI-1867: Mechanism of Action
MRI - 1867: Mechanism of Action 8 Indirect Activation Direct Activation Indirect Inhibition Direct Inhibition 0 Inflammation, Tissue injury Inflammatory Cytokines (TLRs ligands, TNF α , 1 L 1 β ) Smad 2 / 3 - mediated expression of fibrotic genes (αSMA, COL 1 / 3 ,FBN) FIBROSIS CB 1 R CB 2 R TGFR
Slide 10: Opioid-Sparing Pain Management (SBP-101)
Opioid - Sparing Pain Management (SBP - 101) In collaboration with Dr. Alexander Binshtok of Hebrew University, we are developing proprietary, cannabinoid - based, opioid - sparing anesthetics CBD , a known TRPV1 and TRPA1 activator, can be used for “painless” activation of these channels Completed
Slide 11: SBP-101: Mechanism of Action
SBP - 101: Mechanism of Action 10 CBD - Induced, TRPV1 - Mediated, Pain Selective Anesthesia
Slide 12: Intellectual Property
Intellectual Property 11 Licensor Name Issued Patents Est. Expiration Filed Patent Applications National Institutes of Health “Cannabinoid Receptor Mediating Compounds” 2 2033 6 “Pyrazole Derivatives and Their Use As Cannabinoid Receptor Mediators” 1 2035 8 “Cannabinoid Receptor Mediating Compounds”
Slide 13: Team
Team 12 Leadership Team ● Morris C . Laster, M . D .: Co - Chairman, Chief Executive Officer and Director ● Ashish P . Sanghrajka : President and Chief Financial Officer ● Robert J . Gibson, CFA : Vice Chairman, Secretary, Treasurer and Director ● Aharon Schwartz, Ph . D .: Senior Advisor, Chairman
Slide 14: Team (Cont.)
Team (Cont.) 13 Board of Directors ● Morris C . Laster, M . D .: Co - Chairman, Chief Executive Officer and Director ● Joshua R . Lamstein : Co - Chairman and Director ● Robert J . Gibson, CFA : Vice Chairman, Secretary, Treasurer and Director ● Aharon Schwartz, Ph . D .: Senior Advisor, Chairman of
Slide 15: Investment Highlights
Investment Highlights Upon Nasdaq Global Market listing, one of only four pure - play cannabinoid therapeutics companies pursuing FDA pathway ● FDA approval creates real barriers to entry, sustained competitive advantages and eligibility for insurance reimbursement ● Low barriers to entry for non -
Slide 16: Thank You
Thank You /A SCOPUS BIOPHARMA